XOMA Royalty Corporation Annual report [Section 13 and 15(d), not S-K Item 405]

Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - Agenus (Details)

Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - Agenus (Details) $ in Thousands		1 Months Ended	9 Months Ended	12 Months Ended
	Sep. 20, 2018 USD ($) item	Nov. 30, 2020 USD ($)	Sep. 30, 2024 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Agreements
Payments of consideration under RPAs, AAAs and CPPAs				$ 53,000	$ 14,650
Reduction in long-term royalty receivable balance due to receipt of payment				18,938
Acquisition of royalty and commercial payment receivables				45,000
Credit losses on purchased receivables				$ 30,904	1,575
Royalty Purchase Agreement \| Merck Immuno-Oncology Product \| Agenus
Agreements
Amount of milestone payments earned under agreement		$ 10,000
Agenus \| Royalty Purchase Agreement
Agreements
Payments of consideration under RPAs, AAAs and CPPAs	$ 15,000
Acquisition of royalty and commercial payment receivables	$ 15,000
Credit losses on purchased receivables			$ 14,000
Write off of allowance for credit losses			$ 14,000
Allowance for credit losses					$ 0
Agenus \| Royalty Purchase Agreement \| Incyte Immuno-Oncology Assets
Agreements
Royalties entity has right to receive (as a percent)	33.00%
Number of licensed products related to milestone and royalties \| item	6
Milestone payments entity has right to receive (as a percent)	10.00%
Agenus \| Royalty Purchase Agreement \| Merck Immuno-Oncology Product
Agreements
Royalties entity has right to receive (as a percent)	33.00%
Milestone payments entity has right to receive (as a percent)	10.00%
Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones	$ 59,500
Reduction in long-term royalty receivable balance due to receipt of payment		1,000
Amount of milestone payments earned under agreement		$ 1,000